Profile data is unavailable for this security.
About the company
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
- Revenue in SEK (TTM)61.15m
- Net income in SEK-334.52m
- Incorporated1997
- Employees109.00
- LocationBioInvent International ABThe Gamma Building, Ideongatan 1LUND 223 70SwedenSWE
- Phone+46 462868550
- Fax+46 462110806
- Websitehttps://www.bioinvent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arcticzymes Technologies ASA | 116.81m | 17.42m | 1.18bn | 68.00 | 68.10 | 3.80 | 50.03 | 10.13 | 0.3443 | 0.3443 | 2.30 | 6.17 | 0.3562 | 0.4228 | 6.29 | 1,731,471.00 | 5.31 | 15.58 | 5.66 | 17.22 | 95.50 | 96.69 | 14.91 | 33.23 | 12.14 | -- | 0.0327 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
Egetis Therapeutics AB (publ) | 62.80m | -326.90m | 1.31bn | 30.00 | -- | 2.78 | -- | 20.92 | -1.22 | -1.22 | 0.2326 | 1.62 | 0.0913 | 28.00 | 4.33 | 2,325,926.00 | -47.48 | -33.02 | -53.33 | -36.46 | 82.17 | -- | -520.22 | -357.72 | 2.53 | -144.77 | 0.2014 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
Diamyd Medical AB | 186.00k | -139.62m | 1.37bn | 25.00 | -- | 7.19 | -- | 7,340.13 | -1.55 | -1.55 | 0.0021 | 1.96 | 0.0009 | -- | 3.35 | 7,440.00 | -68.99 | -25.46 | -76.65 | -28.37 | -7,386.02 | -1,419.23 | -75,065.59 | -5,896.43 | -- | -90.74 | 0.1391 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
Nanoform Finland Oyj | 27.53m | -263.90m | 1.76bn | 166.00 | -- | 2.34 | -- | 63.82 | -0.2974 | -0.2974 | 0.031 | 0.774 | 0.0287 | 100.58 | 4.29 | 14,687.82 | -27.47 | -27.13 | -30.12 | -29.48 | -576.50 | -604.26 | -958.65 | -1,023.70 | 6.60 | -- | 0.091 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
Devyser Diagnostics AB | 180.50m | -45.90m | 1.81bn | 124.00 | -- | 4.83 | -- | 10.02 | -2.83 | -2.83 | 11.13 | 23.00 | 0.3671 | 1.56 | 5.11 | 1,529,661.00 | -9.33 | -8.97 | -10.65 | -10.15 | 84.76 | 80.14 | -25.43 | -23.91 | 4.34 | -- | 0.1543 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
Cereno Scientific AB | 0.00 | -59.13m | 1.81bn | 5.00 | -- | 7.50 | -- | -- | -0.281 | -0.281 | 0.00 | 0.8598 | 0.00 | -- | -- | 0.00 | -24.71 | -16.81 | -26.65 | -18.26 | -- | -- | -- | -- | -- | -10.70 | 0.1843 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
BioInvent International AB | 61.15m | -334.52m | 2.14bn | 109.00 | -- | 1.74 | -- | 34.97 | -5.08 | -5.08 | 0.929 | 18.73 | 0.041 | -- | 1.29 | 550,927.90 | -22.41 | -17.50 | -23.68 | -18.64 | -- | -- | -547.02 | -131.63 | 13.34 | -- | 0.0169 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
Vicore Pharma Holding AB | 104.24m | -212.94m | 2.15bn | 26.00 | -- | 4.39 | -- | 20.58 | -2.15 | -2.15 | 1.01 | 4.38 | 0.2589 | -- | 14.41 | 4,343,459.00 | -52.89 | -58.65 | -59.34 | -65.58 | -- | -- | -204.27 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
XSpray Pharma AB (publ) | 0.00 | -212.58m | 2.21bn | 26.00 | -- | 4.01 | -- | -- | -7.66 | -7.66 | 0.00 | 20.00 | 0.00 | -- | -- | 0.00 | -33.92 | -18.38 | -36.11 | -19.26 | -- | -- | -- | -- | 2.24 | -- | 0.0536 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
Data as of Jul 05 2024. Currency figures normalised to BioInvent International AB's reporting currency: Swedish Krona SEK
Holder | Shares | % Held |
---|---|---|
Redmile Group LLCas of 31 Dec 2023 | 10.13m | 15.39% |
HBM Partners AG (Investment Management)as of 31 Dec 2023 | 5.08m | 7.71% |
Fj�rde AP-fondenas of 31 Dec 2023 | 4.02m | 6.11% |
Handelsbanken Fonder ABas of 30 Jun 2024 | 1.69m | 2.56% |
Swedbank Robur Fonder ABas of 31 May 2024 | 1.16m | 1.76% |
E. �hman J :or Fonder ABas of 29 Feb 2024 | 551.07k | 0.84% |
Rhenman & Partners Asset Management ABas of 30 Jun 2023 | 450.00k | 0.68% |
SEB Investment Management ABas of 31 May 2024 | 344.25k | 0.52% |
Skandia Investment Management ABas of 31 May 2024 | 325.96k | 0.50% |
FCG Fonder ABas of 31 Dec 2023 | 167.78k | 0.26% |
More ▼
Data from 29 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.